In this episode, we are joined by Dr. Lutz Harms. Lutz is a Senior Director at GW Pharma Germany and has over 20 years of experience in leading orphan drug and specialty businesses in Germany and Europe. He has a proven track record in delivering growth and performance turnarounds. With over 15 years of experience in leadership of orphan drug and specialist medicines businesses in Germany including market access (AMNOG process) and launches/relaunches.  

Topics:  

1. Orphan Drug Trials 

2. Launching Epidyolex 

3. Market Access Requirements  

* Twitter - @TheCannabisRev2         

* LinkedIn - @thecannabisreview        

* Episode Library - https://www.thecannabisreview.ie